Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System

Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are a recent targeted therapy approved for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer. Abemaciclib, palbociclib and ribociclib demonstrated great efficacy and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Martins, Vera, Jesus, Mafalda, Pereira, Luísa, Monteiro, Cristina, Duarte, Ana Paula, Morgado, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610381/
https://www.ncbi.nlm.nih.gov/pubmed/37895811
http://dx.doi.org/10.3390/ph16101340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610381/
https://www.ncbi.nlm.nih.gov/pubmed/37895811
http://dx.doi.org/10.3390/ph16101340

Ejemplares similares